Saudi Arabia Chronic Cough Therapeutics Market Analysis

Saudi Arabia Chronic Cough Therapeutics Market Executive Summary

Saudi Arabia Chronic Cough Therapeutics Market was valued at $107 Mn in 2022 and is estimated to reach $223 Mn in 2030, exhibiting a CAGR of 9.6% during the forecast period.

Chronic cough is a persistent cough that lasts for an extended period, typically defined as lasting for more than eight weeks. Unlike acute coughs, which are often associated with infections or other short-term conditions, chronic cough can be a symptom of an underlying and more persistent health issue. Common causes of chronic cough include respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications. It is important to identify and address the underlying cause of chronic cough through a thorough medical evaluation, as treating the root issue is crucial for effective management. Chronic cough can significantly impact an individual's quality of life and may require a multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists for comprehensive care.

In Saudi Arabia, the prevalence of chronic cough is estimated to be approximately 14.3%. This prevalence specifically considers symptoms associated with Chronic Obstructive Pulmonary Disease (COPD). Chronic cough, stemming from both pulmonary and extra-pulmonary disorders, has the potential to disrupt academic, professional, and social engagements due to its persistent nature.

Pulmonary has commenced a Phase 2 clinical trial for their PBD-1866 inhalation therapy designed to address chronic cough linked to eosinophilic bronchitis. This therapeutic approach is tailored to target a specific inflammatory pathway that is potentially implicated in the manifestation of chronic cough.

Market Dynamics

Market Growth Drivers

Prevalence of Chronic Respiratory Conditions: The high prevalence of chronic respiratory conditions within the population contributes significantly to the demand for chronic cough therapeutics. As chronic cough is often associated with respiratory issues, the market experiences growth due to the need for effective treatment options.

Changing Lifestyles and Environmental Factors: Lifestyle changes and environmental factors, such as air pollution and exposure to allergens, can contribute to the increase in chronic cough cases. The market responds to these challenges by providing therapeutics to address the symptoms and underlying causes.

Aging Population: As per World Bank projections, the proportion of people aged 65 and older in Saudi Arabia is anticipated to rise from 4.4% in 2017 to 9.5% in 2035, and further increase to 18.1% by 2050. The increasing aging population in Saudi Arabia is a significant factor influencing the expansion of the chronic cough therapeutics market. With advancing age, individuals are more prone to respiratory conditions, contributing to a heightened occurrence of chronic cough.

Market Restraints

Limited Awareness and Education: Lack of awareness and education about chronic cough and available treatment options among both healthcare professionals and the general population can hinder the market. This may result in delayed diagnosis and inadequate management of the condition.

Healthcare Infrastructure Challenges: Challenges in the healthcare infrastructure, including limited access to specialized care and diagnostic facilities, can impede the effective diagnosis and treatment of chronic cough. Insufficient healthcare resources may hinder the market's growth potential.

Cultural and Social Stigmas: Cultural and social stigmas associated with respiratory conditions may lead to hesitation in seeking medical attention. Individuals might avoid discussing or addressing chronic cough due to societal perceptions, leading to underreporting and undertreatment of the condition.

Healthcare Policies and Regulatory Landscape

In Saudi Arabia, the supervision of therapeutic drugs is guided by crucial healthcare policies and regulatory entities. The primary regulatory body is the Saudi Food and Drug Authority (SFDA), responsible for ensuring the safety and quality of pharmaceuticals. The Ministry of Health (MOH) collaborates with SFDA to establish healthcare policies, and its Drug Sector oversees pharmaceutical matters, including drug registration and pricing. The National Committee for Drug Control (NCDC) coordinates efforts in drug control, emphasizing the rational use and safety of medications. The National Pharmacovigilance Centre (NPC) is tasked with monitoring pharmaceutical safety, while the Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) indirectly influences drug administration through accrediting healthcare institutions.

Competitive Landscape

Key Players

• GlaxoSmithKline (GSK)
• Pfizer
• McNeil Consumer Healthcare (Johnson & Johnson)
• Procter & Gamble (P&G)
• Reckitt Benckiser Group
• Perrigo Company
• Medtech Products Inc.
• Bionpharma Inc.
• A. Vogel Canada Inc.
• Jamieson Laboratories